References
1. Mathews V, George B, Viswabandya A, et al. Improved clinical outcomes of high risk β thalassemia major patients undergoing a HLA matched related allogeneic stem cell transplant with a treosulfan based conditioning regimen and peripheral blood stem cell grafts. PloS One . 2013;8(4):e61637. doi:10.1371/journal.pone.0061637
2. Lucarelli G, Galimberti M, Delfini C, et al. MARROW TRANSPLANTATION FOR THALASSAEMIA FOLLOWING BUSULPHAN AND CYCLOPHOSPHAMIDE. The Lancet . 1985;325(8442):1355-1357. doi:10.1016/S0140-6736(85)91784-2
3. George B, Viswabandya A, Abraham A, et al. Increased Incidence of Mixed Chimerism with the Use of Fludarabine – Treosulfan Based Conditioning in Patients Undergoing Allogeneic Stem Cell Transplantation for Thalassaemia Major. Biol Blood Marrow Transplant . 2015;21(2):S284-S285. doi:10.1016/j.bbmt.2014.11.451
4. George B, Abraham A, Lakshmi K, et al. Treosulfan Based Conditioning Regimen Is Associated with Better Overall Survival Compared to Busulfan Based Regimens in Older Children with Thalassaemia Major. Biol Blood Marrow Transplant . 2019;25(3, Supplement):S317-S318. doi:10.1016/j.bbmt.2018.12.649
5. Salinger DH, Blough DK, Vicini P, et al. A limited sampling schedule to estimate individual pharmacokinetic parameters of fludarabine in hematopoietic cell transplant patients. Clin Cancer Res Off J Am Assoc Cancer Res . 2009;15(16):5280-5287. doi:10.1158/1078-0432.CCR-09-0427
6. McCune JS, Woodahl EL, Furlong T, et al. A pilot pharmacologic biomarker study of busulfan and fludarabine in hematopoietic cell transplant recipients. Cancer Chemother Pharmacol . 2012;69(1):263-272. doi:10.1007/s00280-011-1736-3
7. Long-Boyle JR, Green KG, Brunstein CG, et al. High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation. Bone Marrow Transplant . 2011;46(1):20-26. doi:10.1038/bmt.2010.53
8. Sanghavi K, Wiseman A, Kirstein MN, et al. Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioning.Transl Res J Lab Clin Med . 2016;175:103-115.e4. doi:10.1016/j.trsl.2016.03.017
9. Mohanan E, Panetta JC, Lakshmi KM, et al. Population pharmacokinetics of fludarabine in patients with aplastic anemia and Fanconi anemia undergoing allogeneic hematopoietic stem cell transplantation.Bone Marrow Transplant . Published online May 8, 2017. doi:10.1038/bmt.2017.79
10. Ivaturi V, Dvorak CC, Chan D, et al. Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant . 2017;23(10):1701-1713. doi:10.1016/j.bbmt.2017.06.021
11. Langenhorst JB, Dorlo TPC, van Maarseveen EM, et al. Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation.Clin Pharmacokinet . 2019;58(5):627-637. doi:10.1007/s40262-018-0715-9
12. Scheulen ME, Hilger RA, Oberhoff C, et al. Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies. Clin Cancer Res Off J Am Assoc Cancer Res . 2000;6(11):4209-4216.
13. Casper J, Freund M. Treosulfan based conditioning for autologous and allogeneic hematopoietic stem cell transplantation. Int J Clin Pharmacol Ther . 2004;42(11):661-662.
14. Hilger RA, Baumgart J, Scheulen ME, et al. Pharmacokinetics of treosulfan in a myeloablative combination with cyclophosphamide prior to allogeneic hematopoietic stem cell transplantation. Int J Clin Pharmacol Ther . 2004;42(11):654-655.
15. Nemecek ER, Guthrie KA, Sorror ML, et al. Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant . 2011;17(3):341-350. doi:10.1016/j.bbmt.2010.05.007
16. Główka FK, Romański M, Teżyk A, Zaba C, Wróbel T. HPLC method for determination of biologically active epoxy-transformers of treosulfan in human plasma: pharmacokinetic application. J Pharm Biomed Anal . 2012;62:105-113. doi:10.1016/j.jpba.2011.12.021
17. ten Brink MH, Ackaert O, Zwaveling J, et al. Pharmacokinetics of Treosulfan in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation: Ther Drug Monit . Published online January 2014:1. doi:10.1097/FTD.0000000000000047
18. Główka F, Kasprzyk A, Romański M, et al. Pharmacokinetics of treosulfan and its active monoepoxide in pediatric patients after intravenous infusion of high-dose treosulfan prior to HSCT. Eur J Pharm Sci Off J Eur Fed Pharm Sci . 2015;68:87-93. doi:10.1016/j.ejps.2014.12.010
19. Koyyalamudi SR, Kuzhiumparambil U, Nath CE, et al. Development and Validation of a High Pressure Liquid Chromatography–UV Method for the Determination of Treosulfan and Its Epoxy Metabolites in Human Plasma and Its Application in Pharmacokinetic Studies. J Chromatogr Sci . 2016;54(3):326-333. doi:10.1093/chromsci/bmv145
20. Bartelink IH, van Reij EML, Gerhardt CE, et al. Fludarabine and exposure-targeted busulfan compares favorably with busulfan/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant . 2014;20(3):345-353. doi:10.1016/j.bbmt.2013.11.027
21. Perkins JB, Kim J, Anasetti C, et al. Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant . 2012;18(7):1099-1107. doi:10.1016/j.bbmt.2011.12.584
22. Russell JA, Kangarloo SB, Williamson T, et al. Establishing a target exposure for once-daily intravenous busulfan given with fludarabine and thymoglobulin before allogeneic transplantation. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant . 2013;19(9):1381-1386. doi:10.1016/j.bbmt.2013.07.002
23. McCune JS, Jacobson P, Wiseman A, Militano O. Optimizing drug therapy in pediatric SCT: focus on pharmacokinetics. Bone Marrow Transplant . 2015;50(2):165-172. doi:10.1038/bmt.2014.235
24. Mathews V, George B, Deotare U, et al. A new stratification strategy that identifies a subset of class III patients with an adverse prognosis among children with beta thalassemia major undergoing a matched related allogeneic stem cell transplantation. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant . 2007;13(8):889-894. doi:10.1016/j.bbmt.2007.05.004
25. Fouzia NA, Edison ES, Lakshmi KM, et al. Long-term outcome of mixed chimerism after stem cell transplantation for thalassemia major conditioned with busulfan and cyclophosphamide. Bone Marrow Transplant . 2018;53(2):169-174. doi:10.1038/bmt.2017.231
26. Common Terminology Criteria for Adverse Events (CTCAE) | Protocol Development | CTEP. Accessed October 13, 2020. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_60
27. Carreras E, Dufour C, Mohty M, Kröger N, eds. The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies . 7th ed. Springer; 2019. Accessed October 13, 2020. http://www.ncbi.nlm.nih.gov/books/NBK553942/
28. Wang X. Firth logistic regression for rare variant association tests. Front Genet . 2014;5. doi:10.3389/fgene.2014.00187
29. Bornhäuser M, Storer B, Slattery JT, et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood . 2003;102(3):820-826. doi:10.1182/blood-2002-11-3567
30. Bonin M, Pursche S, Bergeman T, et al. F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan. Bone Marrow Transplant . 2007;39(4):201-206. doi:10.1038/sj.bmt.1705565
31. Bemer MJ, Sorror M, Sandmaier BM, O’Donnell PV, McCune JS. A pilot pharmacologic biomarker study in HLA-haploidentical hematopoietic cell transplant recipients. Cancer Chemother Pharmacol . 2013;72(3):607-618. doi:10.1007/s00280-013-2232-8
32. McCune JS, Vicini P, Salinger DH, et al. Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration. Cancer Chemother Pharmacol . 2015;75(1):67-75. doi:10.1007/s00280-014-2618-2
33. McCune JS, Mager DE, Bemer MJ, Sandmaier BM, Storer BE, Heimfeld S. Association of fludarabine pharmacokinetic/dynamic biomarkers with donor chimerism in nonmyeloablative HCT recipients. Cancer Chemother Pharmacol . 2015;76(1):85-96. doi:10.1007/s00280-015-2768-x
34. Chung H, Hong KT, Lee JW, et al. Pharmacokinetics of fludarabine and its association with clinical outcomes in paediatric haematopoietic stem cell transplantation patients. Bone Marrow Transplant . 2019;54(2):284-292. doi:10.1038/s41409-018-0260-z
35. Poonkuzhali B, Srivastava A, Quernin MH, et al. Pharmacokinetics of oral busulphan in children with beta thalassaemia major undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant . 1999;24(1):5-11. doi:10.1038/sj.bmt.1701814
36. Chandy M, Balasubramanian P, Ramachandran SV, et al. Randomized trial of two different conditioning regimens for bone marrow transplantation in thalassemia–the role of busulfan pharmacokinetics in determining outcome. Bone Marrow Transplant . 2005;36(10):839-845. doi:10.1038/sj.bmt.1705151
37. Gaziev J, Nguyen L, Puozzo C, et al. Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring. Blood . 2010;115(22):4597-4604. doi:10.1182/blood-2010-01-265405
38. Poonkuzhali B, Chandy M, Srivastava A, Dennison D, Krishnamoorthy R. Glutathione S-transferase activity influences busulfan pharmacokinetics in patients with beta thalassemia major undergoing bone marrow transplantation. Drug Metab Dispos Biol Fate Chem . 2001;29(3):264-267.
39. Chiesa R, Cappelli B, Crocchiolo R, et al. Unpredictability of Intravenous Busulfan Pharmacokinetics in Children Undergoing Hematopoietic Stem Cell Transplantation for Advanced Beta Thalassemia: Limited Toxicity with a Dose-Adjustment Policy. Biol Blood Marrow Transplant . 2010;16(5):622-628. doi:10.1016/j.bbmt.2009.11.024
40. Balasubramanian P, Chandy M, Krishnamoorthy R, Srivastava A. Evaluation of existing limited sampling models for busulfan kinetics in children with beta thalassaemia major undergoing bone marrow transplantation. Bone Marrow Transplant . 2001;28(9):821-825. doi:10.1038/sj.bmt.1703245
41. Balasubramanian P, Desire S, Panetta JC, et al. Population pharmacokinetics of cyclophosphamide in patients with thalassemia major undergoing HSCT. Bone Marrow Transplant . 2012;47(9):1178-1185. doi:10.1038/bmt.2011.254
42. McCune JS, Batchelder A, Deeg HJ, et al. Cyclophosphamide following Targeted Oral Busulfan as Conditioning for Hematopoietic Cell Transplantation: Pharmacokinetics, Liver Toxicity, and Mortality.Biol Blood Marrow Transplant . 2007;13(7):853-862. doi:10.1016/j.bbmt.2007.03.012
43. Mohanan E, Panetta JC, Lakshmi KM, et al. Pharmacokinetics and Pharmacodynamics of Treosulfan in Patients With Thalassemia Major Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.Clin Pharmacol Ther . 2018;104(3):575-583. doi:10.1002/cpt.988
44. Langenhorst JB, van Kesteren C, van Maarseveen EM, et al. Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes. Blood Adv . 2019;3(14):2179-2187. doi:10.1182/bloodadvances.2018029421
45. Molina-Arcas M, Marcé S, Villamor N, et al. Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells.Leukemia . 2005;19(1):64-68. doi:10.1038/sj.leu.2403582
46. Chen S, Wainwright DA, Wu JD, et al. CD73: an emerging checkpoint for cancer immunotherapy. Immunotherapy . Published online June 21, 2019. doi:10.2217/imt-2018-0200
47. Roh M, Wainwright DA, Wu JD, Wan Y, Zhang B. Targeting CD73 to augment cancer immunotherapy. Curr Opin Pharmacol . 2020;53:66-76. doi:10.1016/j.coph.2020.07.001
48. Yu M, Guo G, Huang L, et al. CD73 on cancer-associated fibroblasts enhanced by the A 2B -mediated feedforward circuit enforces an immune checkpoint. Nat Commun . 2020;11(1):515. doi:10.1038/s41467-019-14060-x
49. Allard B, Turcotte M, Stagg J. CD73-Generated Adenosine: Orchestrating the Tumor-Stroma Interplay to Promote Cancer Growth. Dwyer KM, ed. J Biomed Biotechnol . 2012;2012:485156. doi:10.1155/2012/485156
50. Mohanan E, Panetta JC, Lakshmi KM, et al. A 5’UTR Polymorphism in NT5E Gene Influences Outcome in Patients with Acute Myeloid Leukemia Undergoing Hematopoietic Stem Cell Transplantation with Fludarabine Based Conditioning Regimen. Blood . 2016;128(22):984-984. doi:10.1182/blood.V128.22.984.984
51. Jiang T, Xu X, Qiao M, et al. Comprehensive evaluation of NT5E/CD73 expression and its prognostic significance in distinct types of cancers.BMC Cancer . 2018;18(1):267. doi:10.1186/s12885-018-4073-7
52. Vaisitti T, Arruga F, Guerra G, Deaglio S. Ectonucleotidases in Blood Malignancies: A Tale of Surface Markers and Therapeutic Targets.Front Immunol . 2019;10. doi:10.3389/fimmu.2019.02301
53. Thompson LF, Tsukamoto H, Chernogorova P, Zeiser R. A delicate balance. OncoImmunology . 2013;2(1):e22107. doi:10.4161/onci.22107
54. Tsukamoto H, Chernogorova P, Ayata K, et al. Deficiency of CD73/ecto-5′-nucleotidase in mice enhances acute graft-versus-host disease. Blood . 2012;119(19):4554-4564. doi:10.1182/blood-2011-09-375899
55. Geraghty NJ, Watson D, Sluyter R. Pharmacological blockade of the CD39/CD73 pathway but not adenosine receptors augments disease in a humanized mouse model of graft-versus-host disease. Immunol Cell Biol . 2019;97(6):597-610. doi:10.1111/imcb.12251
56. Bernasconi P, Borsani O. Immune Escape after Hematopoietic Stem Cell Transplantation (HSCT): From Mechanisms to Novel Therapies.Cancers . 2020;12(1):69. doi:10.3390/cancers12010069
57. Fausther M. Extracellular adenosine: a critical signal in liver fibrosis. Am J Physiol-Gastrointest Liver Physiol . 2018;315(1):G12-G19. doi:10.1152/ajpgi.00006.2018
58. Tiwari‐Heckler S, Jiang ZG. Adenosinergic Signaling in Liver Fibrosis. Clin Liver Dis . 2019;14(1):1-4. doi:10.1002/cld.777